緑内障治療市場レポート：薬剤クラス別、適応症別、エンドユーザー別、地域別、2025年～2033年

世界の緑内障治療の市場規模は2024年に84億米ドルに達しました。今後、IMARC Groupは、2033年には141億米ドルに達し、2025～2033年の成長率（CAGR）は5.35%になると予測しています。北米が現在市場をリードしているのは、高度なヘルスケアインフラ、認知度の向上、最先端治療へのアクセス、強力な規制支援、緑内障リスクのある高齢人口の多さなどが背景にあります。世界の緑内障の有病率の増加、早期発見のための診断技術の継続的な進歩、眼科における遠隔医療の採用の増加、外科手術における数々の技術革新は、市場を推進している要因のいくつかを表しています。

緑内障は、世界的に永久失明の原因の上位にランクされており、毎年診断される人の数が増加しています。この疾患は一般的に徐々に無症状で進行するため、早期発見が難しく、継続的な治療が必要な患者数が多くなるため、緑内障治療市場は拡大しています。さらに、緑内障に関する社会的認知の向上や教育の改善により、より多くの人々が検診を受けるようになり、早期発見につながっています。早期の介入は、患者が実質的な視神経損傷を受ける前に病気をコントロールすることを目指すため、治療ニーズの増加につながり、市場の成長を支えています。これに加えて、製薬会社やヘルスケア機関からの研究事業への資金提供の増加は、視神経の健康維持に焦点を当てた神経保護治療などの新しい治療法の特定につながっています。このように技術革新が重視されることで、治療の選択肢が増え、それによって市場の選択肢が広がり、緑内障を効果的に管理するための新たな楽観論が患者にもたらされています。

緑内障治療市場動向と促進要因：

手術手技の進歩

手術技術の進歩は、特に低侵襲緑内障手術（MIGS）の出現により、緑内障治療市場に影響を与えています。MIGSは、従来の手術とは対照的に、合併症の減少、回復期間の短縮、手技の簡略化など、より安全な選択肢を提供することで緑内障治療に革命をもたらしています。この進歩は外科医に新たな治療選択肢を提供すると同時に、患者のリスクや不快感を軽減します。さらに、マイクロステントや革新的なドレナージシステムを含む手術器具の開発により、緑内障手術の有効性が向上しています。技術革新の重要な例として、2025年に米国で導入されたアルコンのVoyager（TM）DSLTがあります。これは、最初の完全自動Direct Selective Laser Trabeculoplasty装置です。この装置は、ゴニオレンズや手動によるターゲティングを必要とせず、120のレーザーパルスを提供することでSLTプロセスを合理化し、精度を高め、手技の複雑さを最小限に抑えます。このような技術革新は外科手術に対する信頼を高め、市場の拡大と治療結果の向上を後押しします。

ジェネリック医薬品の成長

緑内障治療のジェネリック医薬品の増加により、費用対効果の高い治療へのアクセスが増加しています。プロスタグランジンアナログのような有名な緑内障治療のジェネリック医薬品は、その有効性を維持しながら、有名ブランドの治療に代わる経済的な治療薬を提供します。この動向は、特に経済的な制約や保険適用の制限に直面する可能性のある患者の治療へのアクセスを向上させるために不可欠です。ジェネリック医薬品はヘルスケア費用の削減に貢献すると同時に、より多くの患者層が緑内障の効果的な治療にアクセスできるようになります。有名薬のジェネリック医薬品を発売する製薬企業が増加するにつれ、競争が激化し、価格の低下と市場アクセスの拡大につながっています。2024年、米国グレンマーク・ファーマシューティカルズ社は緑内障と高眼圧症を治療するトラバタンZ-トラボプロスト点眼液0.004%のジェネリック医薬品を発売しました。同製品はサンド社の基準薬と生物学的に同等であり、グレンマークの眼科製品ポートフォリオを拡大するものです。トラバタンZは2024年9月現在、米国で年間6,620万米ドルの売上を計上しています。

遺伝子治療の進歩

遺伝子治療における最近の進歩は、この疾患に対処するための斬新で独創的な方法を提供しています。科学者たちは、網膜神経節細胞の保護やミトコンドリア機能の改善など、緑内障の根本原因に対処することを目的とした遺伝子治療を研究しています。特定の遺伝子を眼に導入するこれらの治療は、眼圧を下げると同時に、視神経の完全性を保護し、視覚関連細胞の全体的な機能を高めることを目指します。臨床試験における遺伝子治療の進歩により、遺伝子治療は従来の治療に代わる有望な治療法として浮上しており、副作用を抑えながら持続的な利点をもたらす可能性があります。このような先進的な治療法の開発は、患者に緑内障をコントロールするためのより正確で効率的な選択肢を提供することで、市場の拡大を促し、かなりの投資と注目を集めています。2024年、トリニティ・カレッジ・ダブリンの研究者らは、網膜神経節細胞を保護し、ミトコンドリア機能を強化する緑内障の画期的な遺伝子治療を発表しました。AAVでeNdi1遺伝子を導入したこの治療法は、動物モデルやヒトモデルにおいて視覚関連細胞のパフォーマンスを改善しました。スピンアウトしたVzarii Therapeutics社は、この治療法を臨床試験に向けて前進させるために設立されました。

緑内障治療市場成長の促進要因：

高齢者人口の増加

世界の高齢者人口の増加、特に先進国や急速な発展途上国における高齢者人口の増加が、緑内障患者の大幅な増加につながっています。世界保健機関（WHO）は、2030年までに世界の6人に1人が60歳以上になると推定しており、この数字は2050年までに2倍の21億人に達すると予測されています。この人口動態の変化により、緑内障に罹患しやすい患者数が拡大し、効果的な診断方法、代替治療、継続的な管理アプローチの必要性が高まっています。高齢者は緑内障のような長期的な病気にかかりやすく、視力障害を回避するために継続的な治療が必要になることが多いです。そのため、高齢者の増加により、内科的および外科的選択肢を含む新しい治療に対する需要が高まっています。この傾向は、高齢患者特有の要件を満たすカスタマイズされた治療法を策定するための調査事業への投資を促し、市場の成長をさらに後押ししています。

意識の高まりと早期診断

緑内障に関する認知度の向上は、緑内障治療市場の拡大を促す上で極めて重要です。健康キャンペーン、眼科医療機関による取り組み、情報入手のしやすさの向上などが、緑内障の認知度向上に貢献しています。早期発見の重要性を認識する人が増えているため、特にリスクの高いグループの間で定期的な眼科検診の需要が高まっています。早期診断によってタイムリーな介入が可能になり、不可逆的な視力喪失のリスクが軽減され、治療成績が向上します。2024年、アッヴィ・インディアとSightsavers India社は、40歳以上の人々を対象に、緑内障に対する認識を高める15ヶ月のキャンペーンを開始しました。この取り組みでは、早期診断と治療を奨励するため、スクリーニングキャンプ、オンライン支援活動、教育プログラムを実施しました。このような積極的なヘルスケアへのシフトは、緑内障治療、診断ツール、外科的治療に対する需要の増加につながります。その結果、認知度の向上が緑内障治療の採用を直接後押ししています。

ドラッグデリバリーシステムの進歩

徐放性インプラント、穿刺プラグ、注射製剤などの技術革新は、緑内障治療の投与方法を変えつつあります。これらの革新的なシステムは、定期的な点眼が必要で、患者の服薬アドヒアランスがしばしば不十分となる従来の点眼薬よりも、より持続的な効果をもたらします。例えば、徐放性製剤は数週間から数カ月にわたって薬効を持続させることができ、毎日点眼する必要性を最小限に抑え、治療コンプライアンスを向上させます。これは患者の快適性を向上させるだけでなく、均一な治療結果を保証し、最終的に優れた眼圧管理をもたらします。ドラッグデリバリーシステムの強化が重視されるようになり、より洗練された緑内障治療への需要が高まっています。2024年、リップル・セラピューティクスは緑内障の眼圧を下げるための完全生分解性徐放性膀胱内インプラントRTC-620を開発するためのアッヴィとの共同研究を発表しました。リップル社が前臨床開発を担当し、アッヴィ社が臨床試験と商業化を主導します。このインプラントはポリマーや賦形剤を使用せずに反復投与が可能で、炎症リスクを低減します。

目次

第1章 序文

第2章 調査範囲と調査手法

• 調査の目的
• ステークホルダー
• データソース
  • 一次情報
  • 二次情報
• 市場推定
  • ボトムアップアプローチ
  • トップダウンアプローチ
• 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

第5章 世界の緑内障治療市場

• 市場概要
• 市場実績
• COVID-19の影響
• 市場予測

第6章 市場内訳：薬剤クラス別

• プロスタグランジン類似体
• ベータ遮断薬
• アルファアドレナリン作動薬
• 炭酸脱水酵素阻害剤
• 併用薬
• その他

第7章 市場内訳：適応症別

• 開放隅角緑内障
• 閉塞隅角緑内障
• その他

第8章 市場内訳：エンドユーザー別

• 病院
• 眼科クリニック
• 外来手術センター
• その他

第9章 市場内訳：地域別

• 北米
  • 米国
  • カナダ
• アジア太平洋地域
  • 中国
  • 日本
  • インド
  • 韓国
  • オーストラリア
  • インドネシア
  • その他
• 欧州
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン
  • ロシア
  • その他
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • その他
• 中東・アフリカ

第10章 SWOT分析

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

第13章 価格分析

第14章 競合情勢

• 市場構造
• 主要企業
• 主要企業のプロファイル
  • Aerie Pharmaceuticals Inc.
  • Allergan Plc
  • Bausch & Lomb Incorporated（Bausch Health Companies Inc.）
  • Inotek Pharmaceuticals Corp.
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Santen Pharmaceutical Co. Ltd.
  • SIFI S.p.A
  • Teva Pharmaceutical Industries Ltd.

List of Figures

• Figure 1: Global: Glaucoma Therapeutics Market: Major Drivers and Challenges
• Figure 2: Global: Glaucoma Therapeutics Market: Sales Value (in Billion USD), 2019-2024
• Figure 3: Global: Glaucoma Therapeutics Market: Breakup by Drug Class (in %), 2024
• Figure 4: Global: Glaucoma Therapeutics Market: Breakup by Indication (in %), 2024
• Figure 5: Global: Glaucoma Therapeutics Market: Breakup by End User (in %), 2024
• Figure 6: Global: Glaucoma Therapeutics Market: Breakup by Region (in %), 2024
• Figure 7: Global: Glaucoma Therapeutics Market Forecast: Sales Value (in Billion USD), 2025-2033
• Figure 8: Global: Glaucoma Therapeutics (Prostaglandin Analogs) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 9: Global: Glaucoma Therapeutics (Prostaglandin Analogs) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 10: Global: Glaucoma Therapeutics (Beta Blockers) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 11: Global: Glaucoma Therapeutics (Beta Blockers) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 12: Global: Glaucoma Therapeutics (Alpha Adrenergic Agonists) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 13: Global: Glaucoma Therapeutics (Alpha Adrenergic Agonists) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 14: Global: Glaucoma Therapeutics (Carbonic Anhydrase Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 15: Global: Glaucoma Therapeutics (Carbonic Anhydrase Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 16: Global: Glaucoma Therapeutics (Combination Drugs) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 17: Global: Glaucoma Therapeutics (Combination Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 18: Global: Glaucoma Therapeutics (Other Drug Classes) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 19: Global: Glaucoma Therapeutics (Other Drug Classes) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 20: Global: Glaucoma Therapeutics (Open Angle Glaucoma) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 21: Global: Glaucoma Therapeutics (Open Angle Glaucoma) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 22: Global: Glaucoma Therapeutics (Angle Closure Glaucoma) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 23: Global: Glaucoma Therapeutics (Angle Closure Glaucoma) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 24: Global: Glaucoma Therapeutics (Other Indications) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 25: Global: Glaucoma Therapeutics (Other Indications) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 26: Global: Glaucoma Therapeutics (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 27: Global: Glaucoma Therapeutics (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 28: Global: Glaucoma Therapeutics (Ophthalmic Clinics) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 29: Global: Glaucoma Therapeutics (Ophthalmic Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 30: Global: Glaucoma Therapeutics (Ambulatory Surgery Centers) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 31: Global: Glaucoma Therapeutics (Ambulatory Surgery Centers) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 32: Global: Glaucoma Therapeutics (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 33: Global: Glaucoma Therapeutics (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 34: North America: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 35: North America: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 36: United States: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 37: United States: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 38: Canada: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 39: Canada: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 40: Asia Pacific: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 41: Asia Pacific: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 42: China: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 43: China: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 44: Japan: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 45: Japan: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 46: India: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 47: India: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 48: South Korea: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 49: South Korea: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 50: Australia: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 51: Australia: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 52: Indonesia: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 53: Indonesia: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 54: Others: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 55: Others: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 56: Europe: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 57: Europe: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 58: Germany: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 59: Germany: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 60: France: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 61: France: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 62: United Kingdom: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 63: United Kingdom: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 64: Italy: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 65: Italy: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 66: Spain: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 67: Spain: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 68: Russia: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 69: Russia: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 70: Others: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 71: Others: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 72: Latin America: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 73: Latin America: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 74: Brazil: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 75: Brazil: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 76: Mexico: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 77: Mexico: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 78: Others: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 79: Others: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 80: Middle East and Africa: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 81: Middle East and Africa: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 82: Global: Glaucoma Therapeutics Industry: SWOT Analysis
• Figure 83: Global: Glaucoma Therapeutics Industry: Value Chain Analysis
• Figure 84: Global: Glaucoma Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

• Table 1: Global: Glaucoma Therapeutics Market: Key Industry Highlights, 2024 and 2033
• Table 2: Global: Glaucoma Therapeutics Market Forecast: Breakup by Drug Class (in Million USD), 2025-2033
• Table 3: Global: Glaucoma Therapeutics Market Forecast: Breakup by Indication (in Million USD), 2025-2033
• Table 4: Global: Glaucoma Therapeutics Market Forecast: Breakup by End User (in Million USD), 2025-2033
• Table 5: Global: Glaucoma Therapeutics Market Forecast: Breakup by Region (in Million USD), 2025-2033
• Table 6: Global: Glaucoma Therapeutics Market: Competitive Structure
• Table 7: Global: Glaucoma Therapeutics Market: Key Players

The global glaucoma therapeutics market size reached USD 8.4 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 14.1 Billion by 2033, exhibiting a growth rate (CAGR) of 5.35% during 2025-2033. North America currently leads the market because of advanced healthcare infrastructure, increasing awareness, access to cutting-edge treatments, strong regulatory support, and a large aging population at risk for glaucoma. The growing prevalence of glaucoma across the globe, continual advancements in diagnostic technologies for early detection, the rising adoption of telemedicine in ophthalmology, and numerous technological innovations in surgical procedures represent some of the factors that are propelling the market.

Glaucoma ranks among the top causes of permanent blindness globally, with a growing number of individuals being diagnosed annually. The condition typically advances gradually and asymptomatically, complicating early detection and resulting in a larger group of patients needing continuous therapeutic care, thereby broadening the market for glaucoma treatments. Moreover, increasing public awareness initiatives and better education regarding glaucoma are motivating more individuals to undergo screenings, resulting in earlier detections. Earlier intervention leads to an increase in the need for therapeutic treatments as patients aim to control the disease prior to substantial optic nerve damage, supporting the market growth. Besides this, heightened funding from pharmaceutical firms and healthcare institutions in research operations is leading to the identification of new therapies, including neuroprotective treatments focused on maintaining optic nerve health. This emphasis on innovation leads to additional treatment choices, thereby broadening the market offerings and providing patients with renewed optimism for effectively managing glaucoma.

Glaucoma Therapeutics Market Trends/Drivers:

Advancements in Surgical Procedures

Advancements in surgical technology are influencing the glaucoma therapeutics market, especially with the emergence of minimally invasive glaucoma surgeries (MIGS). MIGS is revolutionizing the treatment of glaucoma by providing safer alternatives with reduced complications, quicker recovery periods, and simpler procedures in contrast to conventional surgeries. This advancement provides surgeons with additional treatment options while reducing risks and discomfort for patients. Moreover, developments in surgical instruments, including micro-stents and innovative drainage systems, are improving the effectiveness of glaucoma surgeries. A significant instance of innovation is the 2025 introduction of Alcon's Voyager(TM) DSLT in the US, the initial fully automated Direct Selective Laser Trabeculoplasty apparatus. This instrument streamlines the SLT process by providing 120 laser pulses without requiring a gonio lens or manual targeting, enhancing accuracy and minimizing procedural intricacy. These technological innovations enhance trust in surgical procedures, boosting market expansion and enhancing treatment results.

Growth of Generic Drugs

The increasing availability of generic glaucoma drugs is providing more access to cost-effective therapies. Generic forms of well-known glaucoma medications, like prostaglandin analogs, offer an economical substitute to name-brand treatments while maintaining their effectiveness. This trend is essential for increasing access to treatment, especially for patients who might face financial limitations or restrictions in insurance coverage. Generic medications contribute to lower healthcare expenses while allowing a wider patient demographic to gain access to effective treatments for glaucoma. With the rise of pharmaceutical companies launching generic versions of well-known medications, competition intensifies, leading to lower prices and broader market access. In 2024, Glenmark Pharmaceuticals Inc., USA launched a generic version of Travatan Z-Travoprost ophthalmic solution 0.004%-for treating glaucoma and ocular hypertension. The product is bioequivalent to Sandoz's reference drug and expands Glenmark's ophthalmic portfolio. Travatan Z recorded $66.2 million in annual U.S. sales as of September 2024.

Advancements in Gene Therapy

Recent advancements in gene therapy are providing novel, creative methods for addressing the condition. Scientists are investigating gene therapies aimed at addressing the root causes of glaucoma, such as the protection of retinal ganglion cells and the improvement of mitochondrial functions. These treatments, which involve introducing particular genes to the eye, seek to reduce intraocular pressure while also protecting optic nerve integrity and enhancing the overall function of vision-related cells. With the advancement of gene therapy in clinical trials, it emerges as a hopeful substitute for conventional treatments and may provide lasting advantages with reduced side effects. The creation of these advanced treatments is drawing considerable investment and focus, driving market expansion by offering patients more precise, efficient choices for controlling glaucoma. In 2024, Trinity College Dublin researchers announced a breakthrough gene therapy for glaucoma that protects retinal ganglion cells and enhances mitochondrial function. The therapy, using an AAV-delivered eNdi1 gene, improved vision-related cell performance in animal and human models. A spinout, Vzarii Therapeutics, was formed to advance it toward clinical trials.

Glaucoma Therapeutics Market Growth Drivers:

Growing Geriatric Population

The increasing elderly population worldwide, especially in advanced and swiftly developing nations, is leading to a significant rise in glaucoma cases. The World Health Organization (WHO) estimates that by 2030, one in every six individuals globally will be 60 years or older, a figure anticipated to double by 2050, hitting 2.1 billion. This demographic change is expanding the number of patients vulnerable to glaucoma, leading to a growing need for effective diagnostic methods, treatment alternatives, and continuous management approaches. Senior individuals are more vulnerable to long-term ailments such as glaucoma, which frequently necessitates ongoing treatment to avert vision impairment. Therefore, the rising number of elderly individuals is driving the demand for new treatments, including both medical and surgical options. This trend is encouraging investment in research operations to formulate customized therapies that meet the unique requirements of elderly patients, further bolstering the market growth.

Rising Awareness and Early Diagnosis

Raising awareness regarding glaucoma is crucial for stimulating the expansion of the glaucoma therapeutics market. Health campaigns, efforts by eye-care organizations, and greater information accessibility are all helping to raise awareness about the condition. With an increasing number of people recognizing the significance of early detection, there is a rise in the demand for routine eye examinations, especially among high-risk groups. Early diagnosis allows for timely intervention, reducing the risk of irreversible vision loss and ensuring better treatment outcomes. In 2024, AbbVie India and Sightsavers India initiated a 15-month campaign to raise awareness about glaucoma, focusing on people aged 40 and older. The initiative featured screening camps, online outreach, and educational programs to encourage early diagnosis and treatment. This shift towards proactive healthcare leads to higher demand for glaucoma medications, diagnostic tools, and surgical treatments. As a result, greater awareness is directly driving the adoption of glaucoma therapies.

Advancements in Drug Delivery Systems

Innovations, such as sustained-release implants, punctal plugs, and injectable formulations, are changing how glaucoma treatments are delivered. These innovative systems offer a more enduring effect than conventional eye drops, which necessitate regular application, frequently resulting in insufficient patient adherence. Sustained-release systems, for instance, can provide medication for weeks or even months, minimizing the necessity for daily administration and enhancing treatment compliance. This not only improves patient comfort but also guarantees uniform therapeutic outcomes, ultimately resulting in superior management of intraocular pressure. The heightened emphasis on enhancing drug delivery systems is catalyzing the demand for more sophisticated glaucoma therapies. In 2024, Ripple Therapeutics announced a collaboration with AbbVie to develop RTC-620, a fully biodegradable sustained-release intracameral implant for reducing intraocular pressure in glaucoma. Ripple will handle preclinical development, while AbbVie will lead clinical trials and commercialization. The implant allowed repeat dosing without polymers or excipients, reducing inflammation risk.

Glaucoma Therapeutics Industry Segmentation:

Breakup by Drug Class:

• Prostaglandin Analogs
• Beta Blockers
• Alpha Adrenergic Agonists
• Carbonic Anhydrase Inhibitors
• Combination Drugs
• Others

Prostaglandin analogs represents the largest market segment

The prostaglandin analogs segment in the market is predominantly driven by their efficacy in reducing intraocular pressure with fewer systemic side effects compared to other classes of glaucoma medications. The once-daily dosing convenience of these drugs also contributes to patient compliance, thereby increasing its market demand. Innovation in formulations and delivery mechanisms is another major factor contributing to its market share. Intellectual property expiry and subsequent entry of generics, however, pose a challenge to market growth. Lastly, their versatile compatibility with other classes of glaucoma medications makes them a preferred choice in combination therapies, bolstering the segment's prominence.

On the other hand, the beta blockers, alpha adrenergic agonists, carbonic anhydrase inhibitors, combination drugs and other segments are influenced by a diverse range of factors such as affordability, varied mechanisms of action, and well-established safety profiles. These drugs are often prescribed in cases where Prostaglandin Analogs are contraindicated or not effective. Despite their efficacy, the need for multiple daily dosing can impact patient compliance. Availability of generics in this category also makes it a cost-effective option for treatment.

Breakup by Indication:

• Open Angle Glaucoma
• Angle Closure Glaucoma
• Others

Open angle glaucoma represents the largest market segment

The open-angle glaucoma segment is primarily fueled by its prevalence, constituting the majority of glaucoma cases globally. Increased awareness and advancements in diagnostic techniques have led to earlier and more frequent detection of this condition. The availability of multiple treatment options, ranging from medications to surgeries, offers a comprehensive approach to managing open-angle glaucoma. Aging demographics further amplify the incidence rates, thereby driving glaucoma therapeutics market demand. Government initiatives aimed at eye health contribute to the overall market growth for this segment.

On the other hand, the growth in angle closure glaucoma and other segments is primarily driven by an aging population, as the condition is more prevalent among older adults. Advances in diagnostic technologies have also contributed to the segment's expansion by enabling earlier and more accurate detection of the condition. In addition, the increased awareness about the severity of untreated angle-closure glaucoma, which can lead to blindness, has led to higher demand for effective treatments.

Breakup by End User:

• Hospitals
• Ophthalmic Clinics
• Ambulatory Surgery Centers
• Others

Hospitals accounts for the majority of the market share

Hospitals are major consumers in the glaucoma therapeutics market, given their capability to offer advanced diagnostic and surgical interventions. The consolidation of healthcare facilities and investment in state-of-the-art ophthalmic departments contribute to the segment's growth. Additionally, hospitals are often the first point of contact for emergency eye conditions, thereby positioning them as crucial stakeholders. Public and private insurance coverages also incentivize treatment in hospital settings, increasing patient throughput and consumption of glaucoma medications.

On the other hand, the growth in ophthalmic clinics, ambulatory surgery centers, and other segments can be attributed to the specialized focus on eye care, the availability of advanced diagnostic equipment, and faster patient turnover. Increasing consumer preference for specialized care is also a contributing factor. Decentralization of healthcare services and the expansion of ambulatory surgery centers make these settings accessible for minor procedures and regular check-ups. The growth is further supported by flexible payment options and shorter waiting times.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America exhibits a clear dominance, accounting for the largest glaucoma therapeutics market share

The glaucoma therapeutics market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

The market in the North America region is significantly impelled by high healthcare expenditure, robust insurance frameworks, and the presence of leading pharmaceutical companies are primary drivers. Furthermore, the region is home to a diverse and aging population, thereby creating a natural demand for glaucoma treatments. Technological advancements in drug formulation and delivery, backed by substantial investments in research and development, also fuel glaucoma therapeutics market growth.

Regulatory support in terms of expedited approvals and grants fosters innovation, providing a favorable environment for market expansion. Government initiatives in healthcare education and eye screenings contribute to early diagnosis and, in turn, drive demand for therapeutics. Accessibility to specialty ophthalmic clinics and ambulatory surgery centers adds another layer of convenience, encouraging timely intervention.

The availability of both branded and generic drugs offers options across various price points, catering to a wide consumer base. Furthermore, collaborations between public and private sectors in healthcare initiatives serve to increase awareness as well as facilitate entry and acceptance of novel therapeutic solutions in the market.

Competitive Landscape:

The major players in the market are persistently working to develop more effective and less invasive treatment options. They are investing heavily in clinical trials to produce medicines and devices that provide longer-lasting relief with fewer side effects. Collaborations with research institutions and healthcare organizations are common strategies these key players are adopting. Market leaders are also expanding their portfolios by launching innovative products specifically designed to manage different types of glaucoma. Furthermore, these companies are working diligently to meet stringent regulatory requirements, ensuring that their products are both safe and effective. Furthermore, they are also focusing on patient education and awareness programs as a part of their market expansion strategies, thereby offering a favorable glaucoma therapeutics market outlook.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

• Aerie Pharmaceuticals Inc.
• Allergan Plc
• Bausch & Lomb Incorporated (Bausch Health Companies Inc.)
• Inotek Pharmaceuticals Corp.
• Merck & Co. Inc.
• Novartis AG
• Pfizer Inc.
• Santen Pharmaceutical Co. Ltd.
• SIFI S.p.A
• Teva Pharmaceutical Industries Ltd

Key Questions Answered in This Report

• 1.How big is the global glaucoma therapeutics market?
• 2.What is the expected growth rate of the global glaucoma therapeutics market during 2025-2033?
• 3.What are the key factors driving the global glaucoma therapeutics market?
• 4.What has been the impact of COVID-19 on the global glaucoma therapeutics market?
• 5.What is the breakup of the global glaucoma therapeutics market based on the drug class?
• 6.What is the breakup of the global glaucoma therapeutics market based on the indication?
• 7.What is the breakup of the global glaucoma therapeutics market based on the end user?
• 8.What are the key regions in the global glaucoma therapeutics market?
• 9.Who are the key players/companies in the global glaucoma therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Glaucoma Therapeutics Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Drug Class

• 6.1 Prostaglandin Analogs
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Beta Blockers
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Alpha Adrenergic Agonists
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Carbonic Anhydrase Inhibitors
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Combination Drugs
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast
• 6.6 Others
  • 6.6.1 Market Trends
  • 6.6.2 Market Forecast

7 Market Breakup by Indication

• 7.1 Open Angle Glaucoma
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Angle Closure Glaucoma
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Others
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by End User

• 8.1 Hospitals
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Ophthalmic Clinics
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Ambulatory Surgery Centers
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Others
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Aerie Pharmaceuticals Inc.
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
  • 14.3.2 Allergan Plc
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 Bausch & Lomb Incorporated (Bausch Health Companies Inc.)
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 SWOT Analysis
  • 14.3.4 Inotek Pharmaceuticals Corp.
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
  • 14.3.5 Merck & Co. Inc.
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 Novartis AG
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
    • 14.3.6.4 SWOT Analysis
  • 14.3.7 Pfizer Inc.
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 Financials
    • 14.3.7.4 SWOT Analysis
  • 14.3.8 Santen Pharmaceutical Co. Ltd.
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT Analysis
  • 14.3.9 SIFI S.p.A
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
  • 14.3.10 Teva Pharmaceutical Industries Ltd.
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
    • 14.3.10.4 SWOT Analysis